Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mU36 IgG
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
mU36 IgG is a **mouse-derived monoclonal antibody of the IgG isotype** that specifically binds to the CD44v6 isoform, a cell surface adhesion molecule overexpressed in various malignant epithelial tumors, including squamous cell carcinoma of the head and neck (SCCHN) and certain carcinomas (e.g., esophageal, cervical, and pancreatic). mU36 IgG is used in *experimental radioimmunotherapy and tumor-targeting studies*, typically as the parent molecule for the development of chimeric and humanized antibodies (e.g., bivatuzumab). Its mechanism of action involves antibody-dependent targeting of CD44v6-positive tumor cells, which can be used to deliver radioactive payloads or as an antibody-drug conjugate in oncological research. mU36 IgG has been investigated primarily in imaging, biodistribution, and therapeutic studies in solid tumors expressing CD44v6.
- Other names
- mU36mU-36mU 36mU36-IgGmU-36-IgGmU 36-IgGmU36/IPL Immunoglobulin G
02
Targets
CD44v6 (CD44 variant isoform 6)
Beyond the preview
Go deeper on mU36 IgG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mU36 IgG.